Kobo Biotech Past Earnings Performance
Past criteria checks 0/6
Kobo Biotech has been growing earnings at an average annual rate of 25.5%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually.
Key information
25.5%
Earnings growth rate
25.5%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Kobo Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -55 | 2 | 0 |
30 Sep 23 | 0 | -54 | 2 | 0 |
30 Jun 23 | 0 | -53 | 2 | 0 |
31 Mar 23 | 0 | -56 | 2 | 0 |
31 Dec 22 | 0 | -142 | 734 | 0 |
30 Sep 22 | 0 | -143 | 734 | 0 |
30 Jun 22 | 0 | -151 | 7 | 0 |
31 Mar 22 | 0 | -152 | 739 | 0 |
31 Dec 21 | 0 | -70 | 7 | 0 |
30 Sep 21 | 0 | -114 | 10 | 0 |
30 Jun 21 | 0 | -152 | 10 | 0 |
31 Mar 21 | 0 | -192 | 14 | 0 |
31 Dec 20 | 0 | -208 | 18 | 0 |
30 Sep 20 | 0 | -208 | 18 | 0 |
30 Jun 20 | 0 | -209 | 18 | 0 |
31 Mar 20 | 0 | -210 | 18 | 0 |
31 Dec 19 | 0 | -218 | 19 | 0 |
30 Sep 19 | 0 | -219 | 20 | 0 |
30 Jun 19 | 0 | -220 | 20 | 0 |
31 Mar 19 | 0 | -245 | 21 | 0 |
31 Dec 18 | 0 | -259 | 21 | 0 |
30 Sep 18 | 0 | -258 | 20 | 0 |
30 Jun 18 | 0 | -261 | 24 | 0 |
31 Mar 18 | 0 | -239 | 24 | 0 |
31 Dec 17 | 0 | -180 | 25 | 0 |
30 Sep 17 | 0 | -185 | 28 | 0 |
30 Jun 17 | 0 | -188 | 28 | 0 |
31 Mar 17 | 0 | -192 | 31 | 0 |
31 Dec 16 | 6 | -303 | 38 | 0 |
30 Sep 16 | 61 | -315 | 39 | 0 |
30 Jun 16 | 204 | -232 | 42 | 0 |
31 Mar 16 | 325 | -165 | 43 | 0 |
31 Dec 15 | 494 | -108 | 78 | 0 |
30 Sep 15 | 441 | -113 | 81 | 0 |
30 Jun 15 | 355 | -215 | 85 | 0 |
31 Mar 15 | 291 | -303 | 91 | 0 |
31 Mar 14 | 569 | -326 | 109 | 0 |
Quality Earnings: 531541 is currently unprofitable.
Growing Profit Margin: 531541 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 531541 is unprofitable, but has reduced losses over the past 5 years at a rate of 25.5% per year.
Accelerating Growth: Unable to compare 531541's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 531541 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.3%).
Return on Equity
High ROE: 531541's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.